{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:05:26Z","timestamp":1793131526063,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.seminhematol.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T11:36:24Z","timestamp":1726918584000},"page":"385-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Inflammation in myelodysplastic syndrome pathogenesis"],"prefix":"10.1053","volume":"61","author":[{"given":"Juan Jose","family":"Rodriguez-Sevilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0001","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.09.005_bib0002","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","article-title":"Inflammation: a key regulator of hematopoietic stem cell fate in health and disease","volume":"130","author":"Pietras","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0003","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2020.01540","article-title":"Regulation of the bone marrow niche by inflammation","volume":"11","author":"Mitroulis","year":"2020","journal-title":"Front Immunol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.09.005_bib0004","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2011-12-380113","article-title":"Demand-adapted regulation of early hematopoiesis in infection and inflammation","volume":"119","author":"Takizawa","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3324\/haematol.2018.211342","article-title":"Understanding intrinsic hematopoietic stem cell aging","volume":"105","author":"Mejia-Ramirez","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0006","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?","volume":"8","author":"Fulop","year":"2017","journal-title":"Front Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0007","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.celrep.2016.11.031","article-title":"Chronic Infection depletes hematopoietic stem cells through stress-induced terminal differentiation","volume":"17","author":"Matatall","year":"2016","journal-title":"Cell Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ncb3346","article-title":"Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal","volume":"18","author":"Pietras","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"7240","key":"10.1053\/j.seminhematol.2024.09.005_bib0009","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1084\/jem.20131043","article-title":"Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons","volume":"211","author":"Pietras","year":"2014","journal-title":"J Exp Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2022.06.012","article-title":"Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging","volume":"29","author":"Bogeska","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2643-3230.BCD-22-0176","article-title":"The role of inflammation in the initiation and progression of myeloid neoplasms","volume":"4","author":"Balandran","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0013","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0014","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.stem.2022.05.006","article-title":"Clonal hematopoiesis: mutation-specific adaptation to environmental change","volume":"29","author":"Florez","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2020.09.197","article-title":"Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis","volume":"91","author":"SanMiguel","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","article-title":"Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging","volume":"31","author":"Jakobsen","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: host cell death and inflammation","volume":"7","author":"Bergsbaken","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.09.005_bib0019","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0020","doi-asserted-by":"crossref","first-page":"e20201541","DOI":"10.1084\/jem.20201541","article-title":"Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection","volume":"218","author":"Caiado","year":"2021","journal-title":"J Exp Med"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.09.005_bib0021","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","article-title":"IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells","volume":"125","author":"Schinke","year":"2015","journal-title":"Blood"},{"issue":"6465","key":"10.1053\/j.seminhematol.2024.09.005_bib0022","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.005_bib0023","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keac108","article-title":"Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)","volume":"61","author":"David","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0024","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.3324\/haematol.2019.223305","article-title":"Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Arends","year":"2020","journal-title":"Haematologica"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.09.005_bib0025","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.09.005_bib0026","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.005_bib0027","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2017.181","article-title":"ICUS, CCUS and other four-letter words","volume":"31","author":"Bejar","year":"2017","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100587","article-title":"From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?","volume":"37","author":"Bewersdorf","year":"2019","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0029","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and other acronyms: definition, implications, and impact on practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evidence"},{"issue":"7689","key":"10.1053\/j.seminhematol.2024.09.005_bib0031","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature25022","article-title":"From haematopoietic stem cells to complex differentiation landscapes","volume":"553","author":"Laurenti","year":"2018","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2020.100923","article-title":"Immunometabolic control of hematopoiesis","volume":"77","author":"Hajishengallis","year":"2021","journal-title":"Mol Aspects Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0033","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2022.12.001","article-title":"Clonal hematopoiesis and inflammation\u2014the perpetual cycle","volume":"33","author":"Avagyan","year":"2023","journal-title":"Trends Cell Biol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.05.019","article-title":"TNF-\u03b1 coordinates hematopoietic stem cell survival and myeloid regeneration","volume":"25","author":"Yamashita","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0036","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fimmu.2016.00502","article-title":"Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment","volume":"7","author":"Kovtonyuk","year":"2016","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0037","doi-asserted-by":"crossref","unstructured":"Jakobsen NA, Turkalj S, Zeng AGX, et al. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell. 1127\u20131144.","DOI":"10.1016\/j.stem.2024.05.010"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer cell"},{"issue":"7706","key":"10.1053\/j.seminhematol.2024.09.005_bib0039","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","article-title":"Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host","volume":"557","author":"Meisel","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0040","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.2022016835","article-title":"Aging drives Tet2+\/\u2212 clonal hematopoiesis via IL-1 signaling","volume":"141","author":"Caiado","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0041","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1038\/s41467-023-43697-y","article-title":"Clonal hematopoiesis related TET2 loss-of-function impedes IL1\u03b2-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells","volume":"14","author":"McClatchy","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0042","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1038\/s41467-023-43697-y","article-title":"Clonal hematopoiesis related TET2 loss-of-function impedes IL1beta-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells","volume":"14","author":"McClatchy","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0043","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41375-022-01665-3","article-title":"Il-1r1 drives leukemogenesis induced by Tet2 loss","volume":"36","author":"Burns","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.09.013","article-title":"Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies","volume":"467","author":"Zeng","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.11.008","article-title":"Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients","volume":"80","author":"Zhang","year":"2019","journal-title":"Exp Hematol"},{"issue":"6568","key":"10.1053\/j.seminhematol.2024.09.005_bib0046","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.aba9304","article-title":"Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis","volume":"374","author":"Avagyan","year":"2021","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0047","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2021-150663","article-title":"The transcriptional and epigenetic reprogramming of aged hematopoietic stem cells drives myeloid rewiring in clonal hematopoiesis-associated cytopenias","volume":"138","author":"Ganan-Gomez","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0048","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0049","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/imr.12671","article-title":"Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology","volume":"285","author":"Cicchese","year":"2018","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.immuni.2007.07.010","article-title":"Inflammation directs memory precursor and short-lived effector CD8+T Cell fates via the graded expression of T-bet transcription factor","volume":"27","author":"Joshi","year":"2007","journal-title":"Immunity"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0051","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/jid.2008.286","article-title":"Effects of acute and chronic inflammation on b-cell development and differentiation","volume":"129","author":"Cain","year":"2009","journal-title":"J Investigat Dermat"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0052","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"issue":"7709","key":"10.1053\/j.seminhematol.2024.09.005_bib0053","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"620","key":"10.1053\/j.seminhematol.2024.09.005_bib0054","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Science translational medicine"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0055","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes b-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0056","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41467-021-22458-9","article-title":"B1a and B2 cells are characterized by distinct CpG modification states at DNMT3A-maintained enhancers","volume":"12","author":"Mahajan","year":"2021","journal-title":"Nat Commun"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.005_bib0057","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1158\/0008-5472.CAN-21-1273","article-title":"Activation of notch and myc signaling via b-cell-restricted depletion of dnmt3a generates a consistent murine model of chronic lymphocytic leukemia","volume":"81","author":"Biran","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"New Eng J Med"},{"issue":"6327","key":"10.1053\/j.seminhematol.2024.09.005_bib0059","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"issue":"7569","key":"10.1053\/j.seminhematol.2024.09.005_bib0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2023.05.004","article-title":"Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils","volume":"30","author":"Huerga Encabo","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.005_bib0062","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/blood-2023-184349","article-title":"Mutant natural killer cell dysfunction enables the immune escape of premalignant MDS cell clones","volume":"142","author":"Ganan-Gomez","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0063","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0064","article-title":"The yin-yang of immunity: immune dysregulation in myelodysplastic syndrome with different risk stratification","volume":"13","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ejh.12074","article-title":"Interleukin-17 enhances the production of interferon-\u03b3 and tumour necrosis factor-\u03b1 by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes","volume":"90","author":"Zhang","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0066","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","article-title":"IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome","volume":"145","author":"Kordasti","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0067","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0068","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0069","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.15496","article-title":"Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients","volume":"185","author":"Giovazzino","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0070","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fonc.2016.00172","article-title":"Bone Marrow Immunity and Myelodysplasia","volume":"6","author":"Lambert","year":"2016","journal-title":"Front Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0071","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0609.2008.01182.x","article-title":"Clinical significance of regulatory T cells in patients with myelodysplastic syndrome","volume":"82","author":"Hamdi","year":"2009","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.005_bib0072","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/ajh.25950","article-title":"Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Garcia-Manero","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0073","article-title":"Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome","volume":"14","author":"Tcvetkov","year":"2020","journal-title":"Leukemia Res Rep"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0074","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fonc.2020.01595","article-title":"Overexpression of TIGIT in NK and t cells contributes to tumor immune escape in myelodysplastic syndromes","volume":"10","author":"Meng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-141997","article-title":"Profile of checkpoint molecules expression on bone marrow cell populations in patients with high-risk myelodysplastic syndrome","volume":"136","author":"Tcvetkov","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0076","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/sj.leu.2400844","article-title":"Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes","volume":"11","author":"Kitagawa","year":"1997","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0077","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-0609.2005.00551.x","article-title":"Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis","volume":"75","author":"Stifter","year":"2005","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0078","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0079","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41375-019-0397-9","article-title":"S100A9-induced overexpression of PD-1\/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes","volume":"33","author":"Cheng","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0081","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00262-019-02420-x","article-title":"Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression","volume":"68","author":"Montes","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"97","key":"10.1053\/j.seminhematol.2024.09.005_bib0082","doi-asserted-by":"crossref","first-page":"36929","DOI":"10.18632\/oncotarget.26405","article-title":"Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients","volume":"9","author":"Montes","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0083","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/ncb3385","article-title":"Metabolic regulation of stem cell function in tissue homeostasis and organismal ageing","volume":"18","author":"Chandel","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0084","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1242\/dev.091777","article-title":"Stem cell metabolism in tissue development and aging","volume":"140","author":"Shyh-Chang","year":"2013","journal-title":"Development"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4067162","article-title":"Mitochondrial role in stemness and differentiation of hematopoietic stem cells","volume":"2019","author":"Papa","year":"2019","journal-title":"Stem Cells Int"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0086","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri2991","article-title":"Epigenetics of haematopoietic cell development","volume":"11","author":"Cedar","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0087","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/nrm2766","article-title":"Systems biology of stem cell fate and cellular reprogramming","volume":"10","author":"Macarthur","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0088","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.stem.2011.09.010","article-title":"Metabolic regulation of hematopoietic stem cells in the hypoxic niche","volume":"9","author":"Suda","year":"2011","journal-title":"Cell Stem cell"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0089","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Experiment Molecul Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.molmed.2019.04.006","article-title":"Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation","volume":"25","author":"Verovskaya","year":"2019","journal-title":"Trends Mol Med"},{"issue":"35","key":"10.1053\/j.seminhematol.2024.09.005_bib0091","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"issue":"7673","key":"10.1053\/j.seminhematol.2024.09.005_bib0093","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nature23876","article-title":"Ascorbate regulates haematopoietic stem cell function and leukaemogenesis","volume":"549","author":"Agathocleous","year":"2017","journal-title":"Nature"},{"issue":"7644","key":"10.1053\/j.seminhematol.2024.09.005_bib0094","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature21388","article-title":"Autophagy maintains the metabolism and function of young and old stem cells","volume":"543","author":"Ho","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.stem.2014.07.005","article-title":"Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis","volume":"15","author":"Cabezas-Wallscheid","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0096","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0097","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.2018.211334","article-title":"Microenvironmental contributions to hematopoietic stem cell aging","volume":"105","author":"Ho","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.06.022","article-title":"DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages","volume":"55","author":"Cobo","year":"2022","journal-title":"Immunity"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.005_bib0099","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0100","doi-asserted-by":"crossref","first-page":"e145295","DOI":"10.1172\/jci.insight.145295","article-title":"Obesity-induced inflammation: the impact of the hematopoietic stem cell niche","volume":"6","author":"Bowers","year":"2021","journal-title":"JCI Insight"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.09.005_bib0101","doi-asserted-by":"crossref","first-page":"e163968","DOI":"10.1172\/JCI163968","article-title":"Obesity-induced inflammation exacerbates clonal hematopoiesis","volume":"133","author":"Pasupuleti","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109122","article-title":"Hematologic DNMT3A reduction and high-fat diet synergize to promote weight gain and tissue inflammation","volume":"27","author":"Reyes","year":"2024","journal-title":"iScience"},{"issue":"7715","key":"10.1053\/j.seminhematol.2024.09.005_bib0103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41586-018-0350-5","article-title":"Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer","volume":"559","author":"Wu","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0104","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tem.2020.02.005","article-title":"Interplay between clonal hematopoiesis of indeterminate potential and metabolism","volume":"31","author":"Lee","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41591-021-01396-5","article-title":"The vicious and virtuous circles of clonal hematopoiesis","volume":"27","author":"Furer","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0106","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/ncb3385","article-title":"Metabolic regulation of stem cell function in tissue homeostasis and organismal ageing","volume":"18","author":"Chandel","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0107","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.exphem.2016.04.012","article-title":"Oxidative stress and hypoxia in normal and leukemic stem cells","volume":"44","author":"Testa","year":"2016","journal-title":"Exp Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0108","doi-asserted-by":"crossref","first-page":"e20230088","DOI":"10.1084\/jem.20230088","article-title":"Secretory MPP3 reinforce myeloid differentiation trajectory and amplify myeloid cell production","volume":"220","author":"Kang","year":"2023","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0109","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2159-8290.CD-21-0032","article-title":"Mitochondrial fragmentation triggers ineffective hematopoiesis in myelodysplastic syndromes","volume":"12","author":"Aoyagi","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0110","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","article-title":"The impact of inflammation-induced tumor plasticity during myeloid transformation","volume":"12","author":"Yeaton","year":"2022","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.09.005_bib0111","doi-asserted-by":"crossref","first-page":"11250","DOI":"10.3390\/ijms222011250","article-title":"Myelodysplastic syndromes and metabolism","volume":"22","author":"Balaian","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0112","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"7274","key":"10.1053\/j.seminhematol.2024.09.005_bib0113","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer cell"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0116","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer cell"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0117","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41419-023-06197-x","article-title":"MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes","volume":"14","author":"Giallongo","year":"2023","journal-title":"Cell Death Disease"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.09.005_bib0118","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.3390\/cancers12123520","article-title":"Bioenergetic profiling of the differentiating human mds myeloid lineage with low and high bone marrow blast counts","volume":"12","author":"Poulaki","year":"2020","journal-title":"Cancers"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0119","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1182\/blood-2021-150749","article-title":"Unique metabolic vulnerabilities of myelodysplastic syndrome stem cells","volume":"138","author":"Stevens","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0120","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41467-018-05984-x","article-title":"Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes","volume":"9","author":"Stevens","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0121","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.exphem.2008.01.004","article-title":"Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes","volume":"36","author":"Wulfert","year":"2008","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0122","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/leu.2014.170","article-title":"Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron","volume":"29","author":"Visconte","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.09.005_bib0123","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1038\/s41598-020-66162-y","article-title":"Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study","volume":"10","author":"Cilloni","year":"2020","journal-title":"Scient Rep"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.09.005_bib0124","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1091\/mbc.12.8.2245","article-title":"Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells","volume":"12","author":"Smirnova","year":"2001","journal-title":"Mol Biol Cell"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0125","doi-asserted-by":"crossref","first-page":"e0713","DOI":"10.1097\/HS9.0000000000000713","article-title":"Inflammatory cytokine profiles do not differ between patients with idiopathic cytopenias of undetermined significance and myelodysplastic syndromes","volume":"6","author":"Nielsen","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0126","article-title":"Emerging treatments for myelodysplastic syndromes: biological rationales and clinical translation","volume":"4","author":"Rodriguez-Sevilla","year":"2023","journal-title":"Cell Rep Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.09.005_bib0127","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","article-title":"Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial","volume":"7","author":"Woo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0128","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2023-185259","article-title":"A Phase 2 study of canakinumab in patients with lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia","volume":"142","author":"Rodriguez Sevilla","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bjc.2014.513","article-title":"IRAK signalling in cancer","volume":"112","author":"Rhyasen","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0130","doi-asserted-by":"crossref","first-page":"e78136","DOI":"10.7554\/eLife.78136","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations","volume":"11","author":"Choudhary","year":"2022","journal-title":"eLife"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.09.005_bib0131","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"J Cli Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.09.005_bib0132","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/ajh.23780","article-title":"A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0133","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2023-182289","article-title":"The Dual inflammasome\/myddosome inhibitor HT-6184 restores erythropoiesis in MDS\/AML","volume":"142","author":"Rabinovich","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0134","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1074\/jbc.M106640200","article-title":"Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-\u03b2 on normal hematopoiesis","volume":"277","author":"Verma","year":"2002","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0135","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","article-title":"Reduced SMAD7 leads to overactivation of TGF-\u03b2 signaling in MDS that can be reversed by a specific inhibitor of TGF-\u03b2 receptor I KinaseMAD7 reduction in MDS","volume":"71","author":"Zhou","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.09.005_bib0136","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1078-0432.CCR-14-1380","article-title":"First-in-human dose study of the novel transforming growth factor-\u03b2 receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma","volume":"21","author":"Rodon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0137","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther."},{"issue":"10399","key":"10.1053\/j.seminhematol.2024.09.005_bib0138","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0139","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0141","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.12838","article-title":"An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin","volume":"165","author":"Carrancio","year":"2014","journal-title":"Bri J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.09.005_bib0142","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Letters"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.005_bib0144","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2018-99-119805","volume":"132","author":"Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2024.09.005_bib0145","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood-2019-132065","article-title":"Updated study results of CX-01, an inhibitor of CXCL12\/CXCR4, and azacitidine for the treatment of hypomethylating agent refractory AML and MDS","volume":"134","author":"Huselton","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.09.005_bib0146","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ajh.24746","article-title":"An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes","volume":"92","author":"Daher","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0147","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.HS9.0000843408.31385.3f","article-title":"S129: TAKEAIM LEUKEMIA-a phase 1\/2A study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed\/refractory AML or MDS","volume":"6","author":"Garcia-Manero","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.09.005_bib0148","doi-asserted-by":"crossref","first-page":"9816","DOI":"10.1182\/blood-2022-170185","article-title":"A phase I open label study of fostamatinib, a SYK Inhibitor, in patients with lower-risk myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"140","author":"Montalban-Bravo","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0149","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2023-189226","article-title":"Phase 1b\/2 Study evaluating the safety and efficacy of canakinumab with darbepoetin alfa in patients with lower-risk myelodysplastic syndromes (MDS) who have failed erythropoietin stimulating agents (ESA)","volume":"142","author":"Sallman","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.09.005_bib0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3324\/haematol.2011.044347","article-title":"Value of infliximab (Remicade\u00ae) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group","volume":"97","author":"Baron","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.09.005_bib0151","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-14-1765","article-title":"A Phase I Study of Oral ARRY-614, a p38 MAPK\/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes","volume":"21","author":"Garcia-Manero","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.09.005_bib0152","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-19-1338","article-title":"Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes","volume":"25","author":"Santini","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.09.005_bib0153","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.09.005_bib0154","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0155","article-title":"Vitamin C supplementation in patients with clonal cytopenia of undetermined significance or low-risk myeloid malignancies: results from EVI-2, a randomized, placebo-controlled phase 2 study","author":"Mikkelsen","year":"2024","journal-title":"EHA"},{"key":"10.1053\/j.seminhematol.2024.09.005_bib0156","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2023-186595","article-title":"Phase II study assessing safety and preliminary efficacy of high dose intravenous ascorbic acid in patients with TET2 mutant clonal cytopenias","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T12:53:08Z","timestamp":1734007988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":156,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0037196324001070"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation in myelodysplastic syndrome pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}